Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $14.51 and last traded at $14.79, with a volume of 248542 shares trading hands. The stock had previously closed at $14.77.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the stock. Piper Sandler reduced their price objective on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Citigroup restated a "sell" rating and issued a $14.00 price objective (down from $24.00) on shares of Tandem Diabetes Care in a report on Wednesday, July 9th. Truist Financial assumed coverage on shares of Tandem Diabetes Care in a research report on Monday, June 16th. They issued a "hold" rating and a $24.00 target price on the stock. Robert W. Baird dropped their target price on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research report on Thursday, May 1st. Finally, Stifel Nicolaus lowered their price objective on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $32.71.
Check Out Our Latest Stock Analysis on TNDM
Tandem Diabetes Care Stock Down 0.9%
The company has a debt-to-equity ratio of 1.99, a current ratio of 2.30 and a quick ratio of 1.81. The company has a market capitalization of $974.50 million, a P/E ratio of -5.26 and a beta of 1.48. The stock has a 50-day moving average price of $19.61 and a 200-day moving average price of $23.58.
Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The firm's quarterly revenue was up 22.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.65) EPS. On average, research analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.
Institutional Trading of Tandem Diabetes Care
A number of institutional investors and hedge funds have recently modified their holdings of TNDM. Envestnet Portfolio Solutions Inc. lifted its position in shares of Tandem Diabetes Care by 22.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock valued at $236,000 after acquiring an additional 1,184 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of Tandem Diabetes Care by 17.9% in the first quarter. Oppenheimer Asset Management Inc. now owns 72,752 shares of the medical device company's stock worth $1,394,000 after buying an additional 11,048 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of Tandem Diabetes Care by 27.1% in the first quarter. Janney Montgomery Scott LLC now owns 38,450 shares of the medical device company's stock worth $737,000 after buying an additional 8,210 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after buying an additional 77,451 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Tandem Diabetes Care by 763.3% in the first quarter. GAMMA Investing LLC now owns 42,190 shares of the medical device company's stock worth $808,000 after buying an additional 37,303 shares in the last quarter.
About Tandem Diabetes Care
(
Get Free Report)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tandem Diabetes Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.
While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
